8-K/A: HeartCore Enterprises Amends SEC Filing to Detail $27 Million Financing Agreements and Preferred Stock Issuance

Sentiment:

Capital Raise and Strategic Financing Update 7 July 2025 4:10 PM

📋All filings for Heartcore Enterprises, INC

HeartCore Enterprises, Inc. filed an amended 8-K to correct errors and provide additional details on its $25 million equity purchase agreement and $2 million Series A Convertible Preferred Stock sale with Crom Structured Opportunities Fund I, LP.

Capital raiseEquity Purchase Agreement: The Company has the right, but not the obligation, to sell up to $25,000,000 in common stock to Crom Structured Opportunities Fund I, LP over a two-year period.Securities Purchase Agreement: The Company sold 2,000 shares of Series A Convertible Preferred Stock for $2,000,000 to Crom Structured Opportunities Fund I, LP.Commitment Shares: The Company issued $250,000 worth of common stock (ELOC Commitment Shares) and 750,000 shares of common stock (SPA Commitment Shares) as part of the financing agreements, serving as additional consideration for the Investor's commitment.

Worse than expectedThe financing involves significant potential dilution through the issuance of common stock at a discount to market price (96% of VWAP for advances, 90% of VWAP for preferred conversion) and the issuance of substantial commitment shares (750,000 SPA Commitment Shares and $250,000 worth of ELOC Commitment Shares) for no additional cash consideration.The need for an equity line of credit and convertible preferred stock, coupled with the approval for a reverse stock split, often indicates a company facing challenges in raising capital through less dilutive means or maintaining its stock price above listing requirements.The inclusion of various 'Triggering Events' for the Series A Preferred Stock, which can increase its stated value by 25%, suggests a high-risk profile for the preferred equity and potential for further adverse impact on common shareholders.

Summary

HeartCore Enterprises, Inc. (the Company) filed an Amendment No. 1 on Form 8-K/A to correct errors and provide additional details regarding material definitive agreements previously disclosed.
The Company entered into an Equity Purchase Agreement (Purchase Agreement) with Crom Structured Opportunities Fund I, LP (Investor) on June 30, 2025, granting the Company the right, but not the obligation, to sell up to $25,000,000 in common stock (Advance Shares) to the Investor.
The commitment period for the Purchase Agreement commenced on June 30, 2025, and ends on the earlier of the Investor purchasing the maximum amount, June 30, 2027, or Company termination.
Individual Advance Share purchases must be a minimum of $25,000 and a maximum of the lesser of $500,000 or 50% of the average daily trading value.
The purchase price for Advance Shares is 96% of the volume-weighted average price (VWAP) on the trading day preceding the Advance Date, or the lowest VWAP during the three trading days following the clearing date.
The Company issued $250,000 worth of common stock (ELOC Commitment Shares) to the Investor as a commitment fee for the Equity Purchase Agreement, based on the Nasdaq closing price on June 27, 2025.
The Company also executed a Securities Purchase Agreement (SPA) with the Investor on June 30, 2025, to sell 2,000 shares of Series A Convertible Preferred Stock at $1,000 per share, totaling $2,000,000.
Each Series A Convertible Preferred Stock has a stated value of $1,100 and entitles holders to receive dividends of 10% per annum on the stated value.
In connection with the SPA, the Company issued 750,000 shares of common stock (SPA Commitment Shares) to the Investor for no additional consideration.
The Series A Convertible Preferred Stock is convertible into common stock at a conversion price equal to 90% of the average of the two lowest VWAPs over the five trading days preceding the conversion notice date.
The Company obtained stockholder approval on June 30, 2025, for the issuance of common stock exceeding 19.99% of its issued and outstanding common stock as of that date (equal to 4,412,859 shares), and for a reverse stock split at a ratio of no less than 1-for-2 and no more than 1-for-30.
The proceeds from these agreements are designated to support the Company's software business growth initiatives.
The Company will not issue or sell any Advance Shares (except ELOC Commitment Shares) until the ELOC Registration Statement has been declared effective by the SEC.
The Company agreed to file initial registration statements covering the resale of all shares acquired by the Investor (Advance Shares, ELOC Commitment Shares, Conversion Shares, and SPA Commitment Shares) within 30 calendar days from June 30, 2025, and to have them declared effective by the SEC within 90 days from June 30, 2025.

Sentiment

Score: 3

Explanation: While the company secured significant financing, the terms involve substantial potential dilution for existing shareholders through discounted share issuances and commitment shares. The need for such financing structures and the approval of a reverse stock split suggest underlying challenges or a low stock price, outweighing the positive of securing capital for growth initiatives.

Positives

Secured access to up to $25,000,000 in equity financing through the Equity Purchase Agreement, providing significant capital flexibility.
Raised an immediate $2,000,000 in cash through the sale of Series A Convertible Preferred Stock.
Obtained stockholder approval for potential future share issuances exceeding 19.99% of outstanding shares and for a reverse stock split, enhancing strategic flexibility and compliance with Nasdaq rules.
Proceeds are specifically allocated to support software business growth initiatives, indicating a clear strategic direction for the capital.
The Investor, Crom Structured Opportunities Fund I, LP, is an accredited investor, suggesting a sophisticated and potentially long-term financial partner.

Negatives

The Equity Purchase Agreement is an 'at-the-market' type facility, which can lead to substantial dilution for existing shareholders if the stock price declines during drawdowns.
The conversion price for Series A Convertible Preferred Stock is set at a discount (90% of VWAP), which is inherently dilutive to current common stockholders.
The issuance of 750,000 SPA Commitment Shares and $250,000 worth of ELOC Commitment Shares for no additional cash consideration represents immediate and significant dilution to existing shareholders.
The Company is restricted from entering into other 'Equity Line of Credit' or 'Variable Rate Transactions' without the Investor's prior written consent, potentially limiting future financing options.
The approval of a reverse stock split, while providing flexibility for Nasdaq listing compliance, often signals a low stock price and can be perceived negatively by the market, potentially impacting investor confidence.
The filing is an amendment to correct errors in a prior 8-K, which could suggest initial oversight or complexity in the original disclosure.

Risks

Significant potential for dilution from the issuance of Advance Shares, Conversion Shares, and Commitment Shares, especially if the common stock price declines.
Market price volatility could adversely affect the amount of capital raised through the Equity Purchase Agreement, as the purchase price is tied to VWAP.
Failure to have the ELOC Registration Statement declared effective by the SEC would prevent the Company from issuing most of the Advance Shares, limiting access to the $25 million facility.
The Series A Convertible Preferred Stock holders have a liquidation preference over common stockholders, impacting recovery in a dissolution event.
Various 'Triggering Events' for the Series A Preferred Stock, including failure to deliver conversion shares, insufficient authorized shares, breach of agreements, monetary judgments over $500,000, delisting, or bankruptcy, can automatically increase the stated value of preferred stock by 25%, further disadvantaging common shareholders.
The Company's ability to draw on the Equity Purchase Agreement is contingent on the common stock's lowest traded price exceeding $0.01 per share in the ten trading days preceding an Advance Date.
Bankruptcy, insolvency, or reorganization proceedings against the Company or its subsidiaries would trigger an automatic 25% increase in the stated value of the Series A Preferred Stock.
The Investor is restricted from engaging in short sales or hedging transactions with respect to the common stock during the term of the Purchase Agreement, which might affect their risk management strategies.

Future Outlook

The proceeds from the financing agreements are intended to support the Company's software business growth initiatives. The Company plans to file registration statements for the resale of the newly issued shares and has obtained stockholder approval for a potential reverse stock split, indicating a focus on future capital market activities and strategic adjustments to its capital structure.

Management Comments

The proceeds were to be used to support software business growth initiatives of the Company.

Industry Context

The financing agreements, including an equity line of credit and convertible preferred stock, are common mechanisms for growth-stage technology or software companies to raise capital. This type of financing allows the company to access funds as needed, supporting strategic growth initiatives without immediate full dilution. The stated focus on 'software business growth initiatives' aligns with broader industry trends of continuous innovation, product development, and market expansion in the tech sector.

Comparison to Industry Standards

Equity lines of credit (ELOCs) are a common financing tool for smaller public companies, particularly in growth sectors like software, to provide flexible access to capital. The terms (e.g., 96% of VWAP for advances, 90% of VWAP for preferred conversion) are within the typical range for such facilities, which often involve discounts to market price due to the inherent dilution risk for investors.
The 10% annual dividend on Series A Convertible Preferred Stock is a competitive rate for preferred equity, reflecting the risk profile and the convertible nature of the security.
The commitment fees (ELOC Commitment Shares and SPA Commitment Shares) are standard practice in structured financing arrangements, compensating the investor for committing capital and taking on the associated risks.
The requirement for stockholder approval for issuances exceeding 19.99% aligns with Nasdaq Rule 5635(d), a common corporate governance standard for listed companies to protect existing shareholders from excessive dilution without their consent.
The approval of a reverse stock split is a common strategy for companies whose stock price has fallen below exchange minimums, aiming to increase per-share price and maintain listing compliance, a practice seen across various industries facing similar challenges.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Stockholder Approval for Equity Issuance	Holders of approximately 60% of the overall voting power approved the issuance of common stock in excess of 20% of outstanding shares as of June 30, 2025, and the issuance of all shares pursuant to the Purchase Agreement, SPA, or conversion of Series A Convertible Preferred Stock.	June 30, 2025	Provides the Company with flexibility to issue a significant amount of new shares for financing, potentially leading to substantial dilution for existing shareholders, but necessary for compliance with Nasdaq rules.
Stockholder Approval for Reverse Stock Split	Holders of approximately 60% of the overall voting power approved a reverse stock split at a ratio of no less than 1-for-2 and no more than 1-for-30, with any fractional shares rounded up.	June 30, 2025	Grants the Board discretion to increase the per-share price, potentially to maintain Nasdaq listing compliance, but can be perceived negatively by the market as a sign of distress.
Series A Convertible Preferred Stock Terms	The Company filed a Certificate of Designations for Series A Convertible Preferred Stock, clarifying that it has no voting rights (except on specific adverse changes to its preferences), is entitled to 10% annual dividends, and has a liquidation preference over common stock.	June 30, 2025	Establishes a new class of preferred stock with specific rights and preferences, impacting the capital structure and potentially common shareholder returns and liquidation rights.

Stakeholder Impact

Shareholders: Face significant potential for dilution due to new share issuances at a discount and the issuance of commitment shares. The approved reverse stock split could also impact per-share metrics and market perception. Preferred shareholders gain a liquidation preference and fixed dividends, potentially at the expense of common shareholders.
Employees: No direct impact mentioned, but successful growth initiatives funded by this capital could lead to job security or expansion opportunities.
Customers: No direct impact mentioned, but growth initiatives could lead to improved products or services.
Suppliers: No direct impact mentioned.
Creditors: The capital raise could improve the company's liquidity and financial stability, potentially benefiting creditors. However, the new preferred stock introduces a class of security senior to common equity in liquidation.

Next Steps

The Company will file an Information Statement on Schedule 14C with the SEC describing the stockholder-approved actions (20% Issuance and Reverse Stock Split).
The stockholder-approved actions will not become effective earlier than 20 calendar days following the mailing of the Information Statement.
The Company is required to prepare and file an initial registration statement (ELOC Registration Statement) covering the resale of Advance Shares and Commitment Shares within 30 calendar days from June 30, 2025.
The Company is required to have the ELOC Registration Statement declared effective by the SEC within 90 days from June 30, 2025.
The Company is required to file an initial registration statement (SPA Registration Statement) covering the resale of Conversion Shares and SPA Commitment Shares within 30 calendar days from June 30, 2025.
The Company is required to have the SPA Registration Statement declared effective by the SEC within 90 days from June 30, 2025.
The Company will not issue or sell Advance Shares (except ELOC Commitment Shares) until the ELOC Registration Statement is effective.

Key Dates

Date	Description
2025-06-27	Trading day immediately prior to the effective date of the Purchase Agreement, used to determine the value of ELOC Commitment Shares.
2025-06-30	Date of entry into the Equity Purchase Agreement and the Securities Purchase Agreement; Commencement of the Commitment Period for the Equity Purchase Agreement; Closing date for the sale of Series A Convertible Preferred Stock; Date of stockholder approval for the 20% Issuance and Reverse Stock Split; Date the Certificate of Designations of Preferences and Rights of Series A Convertible Preferred Stock was filed.
2025-07-01	Original Current Report on Form 8-K filing date; Date the Company issued a press release announcing the agreements.
2025-07-07	Date of filing of this Amendment No. 1 on Form 8-K/A.
Within 30 calendar days from 2025-06-30	Deadline for the Company to prepare and file the initial ELOC Registration Statement and SPA Registration Statement.
Within 90 days from 2025-06-30	Deadline for the ELOC Registration Statement and SPA Registration Statement to be declared effective by the SEC.
2025-06-30	End of the Commitment Period for the Equity Purchase Agreement (if the Maximum Commitment Amount is not reached earlier).
20 calendar days following mailing of Information Statement	Earliest effective date for the stockholder-approved actions (20% Issuance and Reverse Stock Split).

Recommendation

hold

Keywords

HeartCore Enterprises, HTCR, SEC filing, equity purchase agreement, Series A Convertible Preferred Stock, capital raise, financing, dilution, stock split, corporate governance, risk management, software business, Nasdaq, Crom Structured Opportunities Fund I, LP, 8-K/A

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.